DiagnaMed, a healthcare company using artificial intelligence, has started a new partnership programme called CERVAI Healthcare Provider Network.

This programme lets healthcare providers including hospitals and clinics in Canada and the USA use DiagnaMed’s brain health AI platform.

The healthcare company claims that CERVAI is the first of its kind in the world.

The AI platform CERVAI comprises Brain Age Estimation and Brain Health Assessment tools that estimate brain’s age and assess its health, respectively, thereby helping people take care of their brain health.

Brain Age leverages special headsets and machine learning to perform its tasks.

In the future, CERVAI will use OpenAI’s GPT platform to make personalised treatment plans.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

DiagnaMed chairman and CEO of Fabio Chianelli said: “As we near the commercial launch for CERVAI, our novel brain health AI platform, we are excited to build our network of healthcare providers seeking to provide value added services, research and clinical care for their patients who want to take control of their brain health.

“Similarly, we will soon launch additional network programmes for enterprise organisations, athletic teams, and personal at-home use.”

According to the company’s website, CERVAI helps improve brain health, especially for mental and brain disorders.

It records brain data, helping doctors and patients see how healthy the brain is and what needs attention.

In addition, CERVAI can screen conditions such as Alzheimer’s or Parkinson’s in their initial stages.

Last month, Fabio Chianelli stated: “We expect to launch CERVAI in Q4-2023. CERVAI is for people who want to take control of their brain health.

“We aim to have CERVAI available at hospitals, doctor offices, clinics, pharmacies, and homes – similar to where blood pressure monitors are used.”